Introduction
Although osteoarthritis (OA) is the most common musculoskeletal condition and is a major cause of pain, disability, and loss of quality of life (1) , there is no well-established disease or structure-modifying therapy. Current treatments for OA aim at relieving symptoms (mostly pain) and improving function. Because no single intervention is entirely effective, most programs combine non-pharmacologic and pharmacologic therapies (2, 3) . An often used pharmacologic therapy in OA involves intra-articular (IA) hyaluronic acid (HA), sometimes referred to as viscosupplementation (4) (5) (6) . From the current debate there are significant controversies concerning the potential effect of IAHA in the treatment of OA.
Several systematic reviews have suggested that IAHA has only a marginal, if any, effect compared with placebo (7) (8) (9) (10) (11) , whereas others have reported robust efficacy (12) (13) (14) (15) (16) (17) . The premise for performing a meta-analysis is to combine the results of all relevant trials addressing the same clinical question to give a more precise, and hopefully unbiased, estimate of the treatment effect. However, if this combination of trials builds on serious inconsistency, a summarized estimate may have no interpretable meaning. Judgment of the extent of heterogeneity is based on similarity of point estimates, extent of overlap of confidence intervals, and statistical criteria including tests of heterogeneity and inconsistency indices (18) . When inconsistency is large and unexplained, rating down the quality of evidence is appropriate, particularly if some studies suggest substantial benefit whereas others indicate no effect. By investigating the sources of heterogeneity among included trials, researchers can identify sources of bias in the summary effect measure (19) . Such inquiries may also yield insights into whether certain patients are more likely to experience benefits of a treatment.
To explain the controversy around the use of IAHA for OA, while emphasizing the need for evidence-based research (20, 21) , a protocol was initiated for the systematic review of existing evidence with an AMSTAR assessment (22) 
(See Appendix 1).
The objective was to evaluate evidence that assesses the efficacy and safety of IAHA in patients with symptomatic OA by carrying out a systematic review and meta-analysis to explore potential reasons and contextual factors which may explain the discrepant trial results.
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Materials and Methods
The search for the systematic review at the meta-analysis was performed according to the recommendations in The Cochrane Handbook for Systematic Reviews of Interventions (23) , and the findings were reported according to the -Preferred Reporting Items for Systematic Reviews and Meta-Analyses‖ (PRISMA) statement (24) . The methods of analysis and the inclusion criteria were specified in advance and registered in the international Prospective
Register of Systematic Reviews (PROSPERO registration no. CRD42014007284; the protocol is available in Appendix 1).
Eligibility criteria
Randomized and quasi-randomized clinical trials comparing IAHA with IA physiological saline injection or with non-intervention control in adults diagnosed with OA according to American College of Rheumatology (ACR) criteria (25) or equivalent were considered eligible for inclusion in the meta-analysis. No restrictions were applied concerning race, sex, joint, type of HA, molecular structure, molecular weight, number of injections per cycle, number of cycles, or follow-up duration. Studies with an active control group, and IAHA following a surgical procedure were excluded.
Information sources and search strategy
Two reviewers (MJ and HBa) Manual searches, including scrutinizing of reference lists of identified systematic reviews were performed. The last 2 years of specialist journals and conference proceedings, including ACR, OARSI and EULAR were also searched. Unpublished trials were sought by correspondence with experts in the field of OA and IAHA and by searching in http://clinicaltrials.gov and http://apps.who.int/trialsearch/. No language, publication date or publication status restrictions were imposed. The literature search for potentially eligible studies (conducted by MJ and HBa) was supervised by an experienced research librarian and documentalist (EMB) (26).
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Study selection
Eligibility assessment was performed independently by two reviewers (MJ, HBa), who screened all relevant references by title and abstract. Studies not fulfilling eligibility criteria were rejected. Reports of the remaining studies were read in full text. Disagreement was resolved by consensus or with help from a third reviewer (RC/HBl).
Risk of bias in individual studies
Study quality (i.e., internal validity) and the potential risk-of-bias in the eligible trials were included in the meta-analysis (27, 28) . Two reviewers (MJ, HBa) independently assessed the study quality using the risk-of-bias tool recommended by Cochrane Collaboration (23). The following risk-of-bias items were included: (1) sequence generation; (2) allocation concealment; (3a) blinding of patients; (3b) blinding of personnel; (4) incomplete outcome data addressed (i.e., using an appropriate intention to treat (ITT) population; a modified ITT was considered adequate if dropout took place before treatment was initiated if judged that the blinding had not been broken); and (5) selective outcome reporting, together with other bias domains defined as (a) funding and (b) single vs. multi center.
Each trial was assigned an overall Risk of Bias term: -Low Risk‖ denoted that all domains were reported adequately; -Unclear risk" defined that at least one domain was unclear; and -High risk‖ denoted that at least one of the domains was inadequate (29) .
Disagreement about the risk-of-bias judgment was resolved by consensus, and if agreement could not be reached, a third reviewer (RC) was involved in order to reach consensus of the overall risk-of-bias. Further details are available in the protocol (Appendix 1).
Data collection process and data items
A customized data extraction sheet was developed, pilot-tested, and refined accordingly. The selection of the appropriate outcome domains was based on the recommendations from OMERACT (31), where pain is considered as primary outcome in OA (32). When data were reported based on more than one outcome measurement instrument, the proposed hierarchical list of patient-reported outcomes for meta-analyses of knee OA trials was used (33, 34) . When outcomes were reported at several time points, preference was given to data assessments conducted 3 months (range: 8-16 weeks) following the completion of the intervention. If assessments were not available, the long-term follow-up, defined as 6 months from completion of intervention (range: 4-7 months) was extracted. If none of the prespecified time points were available, data were extracted from the end of intervention to 7
weeks following the completion of the intervention (range 0-7 weeks).
Statistical analysis
The effect size was expressed as a standardized mean difference (SMD), defined by dividing the difference in means by the pooled standard deviation (SD). The primary advantage of the SMD is the fact that it provides a common metric (35); a minimal important difference (MID) of 0.2 SMD was pre-specified, as referred to in Behavioral Science as the lower boundary of a small effect (36 A priori a -relevant study-level covariate‖ was defined as a covariate that would decrease the between-study variance was defined (19, 44) , (estimated Tau-squared [T 2 ]) as a consequence of inclusion in the (mixed effects) statistical model (30, 45) . Analyses were performed using STATA V.12 (Stata Corp, Texas, USA).
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Results
Search results
The literature search identified 3,021 references leaving 1,963 references after removal of duplicates. The titles and abstracts of these were screened for inclusion (Figure 1 (11,216 patients) had adequately reported results, described in 71 trials (72%). Results were not extractable, not located, or unpublished in 30 comparisons (described in 28 trials).
Included studies
As presented in Table 2 , the mean age of the patients in the included trials ranged from 38 to 72 years with a median of 62 years, and the mean duration of symptoms ranged from 1 to 22 years with a median (of means) being 6 years. The mean number of cycles ranged from one to four cycles with a median of one cycle. The mean number of injections in each cycle ranged from 1 to 11 with a median of 3 injections. The average duration of followup ranged from 0 to 36 weeks with a median of 10 weeks. The majority of the trials (83 of the 99 trials) tested the effect of IAHA in patients with OA of the knee. The remaining 16 trials were as follows: 5 trials on hip OA (i43, i56, i57, i62, i89) , 2 trials on OA in the hand (i49, i55), 4 trials on OA in the ankle and foot (i44, i48, i64, i68) , 3 trials on temporomandibular joint OA (i6, i61, i66) and 2 trials (describing 3 comparisons) on shoulder OA (i46, i70).
Methodological characteristics
Methodological characteristics in eligible trials were assessed for accuracy. These trials are listed in Table 3 . Adequate sequence generation was reported in 34 trials (39%); 30 trials (34%) reported adequate concealment of allocation; 38 trials (43%) were judged to have adequate blinding of patients; and 52 trials (59%) were judged having adequate blinding of outcome assessor. Twenty-six trials (30%) used an adequate analysis based on the intention to treat (ITT) principle. Thirty-seven trials (42%) had adequate outcome reporting. The overall risk-of-bias in the individual studies were considered -Low Risk‖ in 8 trials (9%),
-Unclear Risk‖ in 16 trials (18%), and -High Risk‖ in 64 trials (73%). For -Other risk-ofbias‖, 6 trials (7%) were reported as being free of industry support, and 44 trials (50%) were reported as multicenter trials.
Pain
The overall meta-analysis of 85 comparisons revealed that IAHA had an effect size of -0.39
[-0.47;-0.31; P<0.001], meeting the pre-specified MID (Figure 2 ). An I 2 of 73% indicated, however, a substantial degree of heterogeneity, which was visually evident from the wide scatter of effect estimates with little overlap in their confidence intervals. The potential smallstudy bias was examined by using a fixed-effect analysis resulting in a combined SMD of - The funnel plot depicts evidence of considerable asymmetry (confirmed by an Eggers test, P<0.001), indicating a high risk of publication and/or reporting biases ( Figure 3 ). Thus, in order to adjust for the possible selective outcome reporting, additional analyses included comparisons with number of participants extractable, assigning 24 comparisons null findings (i5, i6, i18, i25, i26, i36, i39, i49, i62, i65, i72, i74, i75, i77, i84, i93-99) Consequently, the overall risk-of-bias, reported blinding of personnel, and trial sizes explained a significant part of the heterogeneity. Other factors leading to a relevant reduction in tau 2 of heterogeneity were (prioritized): multicenter design (17.4%), incomplete data addressed (13%), number of injections (12.1%), follow-up duration (12%), and independence of industry support (11.7%), all with a significant P-value for interaction (P<0.032).
Furthermore, the stratified analysis showed an effect size of -0.34 [-0.41; -0.27] for IA saline as control vs. IAHA and an effect size for non-intervention control vs. IAHA of -0.70 [-1.23; -0.26] , with a reduction in tau from 0.14 to 0.12 (12.9%), but P-value for interaction not being statistical significant.
In addition a stratified analyses according to the number of high risk-of-bias domains as well as low risk-of-bias domains was performed. Apparently, by stratifying according to the number of low risk-of-bias domains, the amount of heterogeneity is reduced (tau 2 reduced from 0,142 to 0.128) with a P-value indicating a statistically significant interaction (i.e. the effect size vary according to the number of low risk-of-bias domains and the analyses showed larger effect size in studies with higher risk-of-bias) (Appendix 2).
Safety
The meta-analysis of serious adverse events (SAE) was calculated based on the 71 trials included in the main meta-analysis. Sixty-one trials reported on SAE ( Figure 5 ), and 17 of these trials reported one or more cases of SAEs observed in each group. The trials that did not report SAE are shown in the analyses as -excluded‖ (i23, i28, i40, i41, i61, i76, i78, i80, i82, i83, i85 
Discussion
The overall meta-analysis, including 71 trials, with 85 comparisons, showed a large degree of heterogeneity and indications of small-study bias. The main result of the analysis was the finding of a small, but clinically relevant, effect of IAHA in patients with OA, showing a reduction of pain in accordance with previous meta-analyses (12) (13) (14) (15) (16) (17) . In contrast, if evidence was only based on low-risk of bias studies, no effect of IAHA was detected at all. Metaanalyses of randomized trials begin as high-quality evidence, but the accumulated evidence is frequently downgraded as a result of limitations in study design (e.g., risk-of-bias), imprecision of estimates (wide confidence intervals), heterogeneity, indirectness of evidence, and publication bias (46). The poor methodological quality and reporting quality of many of the included trials (47) added yet another major limitation of studies being inconsistent (18) and having substantial risk of publication bias (48). These limitations reduced confidence in the estimate, suggesting a downgrade of the quality of evidence to low (49) . Further downgrading to very low quality of evidence is necessary, because overall risk-of-bias reduced some of the observed heterogeneity. Blinding aspects and differences in results from large trials compared to smaller trials also reduced heterogeneity and helped to elucidate the risk-of-bias. Thus, based on relatively easily accessible data, the true effect is likely to be substantially lower than the initially estimated effect size of -0.39 [-0.47 to -0.31] . However, various modified models could potentially allow us to increase the -certainty‖. To a large extent an adjustment for the selective reporting is possible (incl. publication bias) by adding -null effects‖ for the 24 comparisons -without data‖. Hence, this meta-analysis with ‗low quality evidence' was able to present an effect size associated with IAHA in OA patients of -0.30 [-0.37;-0.23 ] (95% prediction interval: -0.87 to 0.26), tentatively adjusting for selective outcome reporting.
Controversy over the clinical value of IAHA is fomented by inconsistent results from former meta-analyses. Eleven meta-analyses were found and assessed according to AMSTAR to be of different methodological quality. Six reviews (12) (13) (14) (15) (16) (17) concluded that IAHA was more effective than saline, or placebo; whereas five reviews (7) (8) (9) (10) (11) were cautious to conclude on the effectiveness or concluded that the effect was not clinically relevant. Among the possible explanations for the differences in estimates on benefits is the different pain outcomes used in the meta-analyses. This study's meta-analysis used the hierarchy of pain outcomes based on the responsiveness of the outcome measures (33), whereas former metaanalyses (7, 10) used other recommended outcome hierarchies (50). In addition, this metaanalysis included IAHA for OA not only in the treatment of knee joints but also in hip and other joints (ankle, foot, temporomandibular joint, shoulder and hand). The literature on joints other than the knee is not as robust, and the stratification of joints suggested an effect size of -0.13 [-0.40 . Furthermore, differences in time points could explain some of the discrepancies among the meta-analyses, an explanation that corresponds to the findings from Campbell and colleagues (53). In this meta-analysis, the pre-specified timepoint hierarchy found the largest effect in trials with short-term follow-up, which is consistent with other meta-analyses
showing the largest effect size at 8 weeks (12, 13, 16) . In contrast, other meta-analyses demonstrated the significantly greatest effect at 3 and 6 months (7, 8) .
The choice of comparator for IAHA could also be of great importance for the estimate. The present meta-analysis compared IAHA with saline or non-intervention control as a comparator. Furthermore, this review excluded trials performing IAHA as a part of postoperational treatment and where the included patient group had a mixture of diagnoses, whereas other meta-analyses also included post-surgical IAHA and mixed diagnoses as a comparator (7, 9, 10) . When stratifying, this meta-analysis showed an effect size of -0. Unfortunately only 17 trials contributed data to the analysis due to that the rest of the trials reported zero events in both study groups. An RR can therefore be argued to be inappropriate statistics for the available data since a vast part of the data is disregarded. Sixty-one trials in this meta-analysis reported SAE, and in a substantial part of these trials the reporting lacked transparency. It would be in the interest of health professionals and patients to get better evidence for the IAHA treatment in the future. This possibility could occur only if large trials of good methodological quality following the CONSORT statement with transparency in reporting regarding both efficacy and safety (58, 59) existed for analysis.
This meta-analysis finds the benefit of IAHA on pain in patients with OA to be small, but clinically potentially relevant, reaching the minimal important difference. Guideline panels should, however, be aware that significant methodological issues around these findings reduce our confidence in the estimate. We conclude that there is low-quality evidence for the Forest plot of differences in pain intensity expressed as effect size comparing the effects of any type of intraarticular hyaluronic and sham or no intervention on pain in 85 comparisons in available trials.
ES represents the effect size, Hedges's 'g', SMD
Blue shading represents the area of clinical equivalence smaller than minimal important difference
Figure 3
Funnel plot for effects on pain Area outside of the dashed line displays significant P-value >0.05 and inside the dashed line is nonsignificant.
Figure 4
Results of stratified analyses of pain outcomes Tau 2 represents the between study variance P-value for interaction from test for trend Blue shading represents the area of clinical equivalence smaller than minimal important difference.
Figure 5
Serious Adverse Events
Results of meta-analysis of serious adverse events in 71 trials. Note that 11 trials did not report serious adverse events and did not contribute to the analysis and are shown as -excluded‖.
Two trials are located from one publication (91) but report on SAE separately RD: Risk Difference 22 Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis and Cartilage. 2004; 12(8) 
